Nevirapine Vocate (Nevirapine)

Nevirapine is an antiretroviral drug that targets HIV‑1 reverse transcriptase, a key enzyme in the viral replication cycle.

• HIV‑1 infection: reduces plasma viral load when used in combination with other antiretrovirals.
• Pediatric HIV‑1 infection: provides viral suppression in children as part of age‑appropriate regimens.
• Treatment‑experienced HIV patients: offers an alternative NNRTI option for those with prior therapy exposure.

• Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, inducing conformational changes that inhibit the enzyme’s activity. This blockade prevents the transcription of viral RNA into DNA, thereby halting the replication of HIV within host cells and reducing viral load in the bloodstream.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Rash: mild to moderate skin eruptions.
• Nausea: occasional gastrointestinal discomfort.
• Fatigue: general feeling of tiredness.
• Headache: transient cranial pain.
• Insomnia: difficulty falling or staying asleep.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe mucocutaneous reaction.
• Hepatotoxicity: elevated liver enzymes or liver failure.
• Severe skin reactions: toxic epidermal necrolysis.
• Hypersensitivity syndrome: fever, rash, organ involvement.
• Hepatic necrosis: rare but life‑threatening liver injury.
• Anaphylaxis: acute allergic response requiring immediate care.

Before initiating therapy, clinicians should assess patient history and monitor for potential risks.

• Liver function monitoring: perform baseline and periodic liver enzyme tests.
• Rash assessment: examine skin regularly for early signs of severe reactions.
• Avoid concurrent potent CYP3A inducers: may reduce nevirapine exposure.
• Caution in hepatitis B/C co‑infection: increased risk of liver toxicity.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Rifampicin: strong CYP3A inducer that markedly lowers nevirapine levels.
• St. John’s wort: herbal CYP3A inducer reducing efficacy.
• Carbamazepine: enzyme inducer leading to subtherapeutic concentrations.
• Phenytoin: reduces nevirapine exposure via hepatic induction.
• Efavirenz: concurrent NNRTIs may increase toxicity.

Moderate Interactions (Monitor Closely)

• Ritonavir-boosted protease inhibitors: may increase nevirapine plasma levels.
• Azole antifungals (e.g., fluconazole): can raise nevirapine concentrations.
• Oral contraceptives: nevirapine may reduce hormonal efficacy; consider alternative contraception.
• Methadone: may require dose adjustment due to altered metabolism.
• Anti‑tuberculosis drugs (excluding rifampicin): monitor liver function closely.